



(51) International Patent Classification:

C07D 487/04 (2006.01) *A61P 35/00* (2006.01)
A61K 31/519 (2006.01) *A61P 37/00* (2006.01)
A61P 29/00 (2006.01)

(21) International Application Number:

PCT/IB2015/053975

(22) International Filing Date:

27 May 2015 (27.05.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

14170408.0 28 May 2014 (28.05.2014) EP

(71) Applicant (for all designated States except US): **NOVARTIS AG** [CH/CH]; Lichtstrasse 35, CH-4056 Basel (CH).

(72) Inventors; and

(71) Applicants (for US only): **PISSOT SOLDERMANN, Carole** [FR/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **QUANCARD, Jean** [FR/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **SCHLAPBACH, Achim** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **SIMIC, Oliver** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH). **TINTEL-NOT-BLOMLEY, Marina** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach,

CH-4002 Basel (CH). **ZOLLER, Thomas** [DE/CH]; Novartis Pharma AG, Novartis Institutes for Biomed. Research, Postfach, CH-4002 Basel (CH).

(74) Common Representative: **NOVARTIS AG**; Lichtstrasse 35, CH-4056 Basel (CH).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.


(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

[Continued on next page]

(54) Title: NOVEL PYRAZOLO PYRIMIDINE DERIVATIVES AND THEIR USE AS MALT1 INHIBITORS



(I)

(57) Abstract: The present invention describes new pyrazolo-pyrimidine derivatives of formula (I) or a pharmaceutically acceptable salt thereof; (I) wherein, R1 is halogen, cyano, or C₁-C₃alkyl optionally substituted by halogen; R2 is C₁-C₆alkyl optionally substituted one or more times by C₁-C₆alkyl, C₂-C₆alkenyl, hydroxyl, N,N-di-C₁-C₆alkyl amino, N-mono-C₁-C₆alkyl amino, O-Rg, Rg, phenyl, or by C₁-C₆alkoxy wherein said alkoxy again may optionally be substituted by C₁-C₆alkoxy, N,N-di-C₁-C₆alkyl amino, Rg or phenyl; C₃-C₆cycloalkyl optionally substituted by C₁-C₆alkyl, N,N-di-C₁-C₆alkyl amino or C₁-C₆alkoxy-C₁-C₆alkyl, and/or two of said optional substituents together with the atoms to which they are bound may form an annulated or spirocyclic 4 - 6 membered saturated heterocyclic ring comprising 1 - 2 O atoms; phenyl optionally substituted by C₁-C₆alkoxy; a 5 - 6 membered heteroaryl ring having 1 to 3 heteroatoms selected from N and O said ring being optionally substituted by C₁-C₆alkyl which may be optionally substituted by amino or hydroxy; Rg; or N,N-di-C₁-C₆alkyl amino carbonyl; and R is phenyl independently substituted two or more times by Ra, 2-pyridyl independently substituted one or more times by Rb, 3-pyridyl independently substituted one or more times by Rc, or 4-pyridyl independently substituted one or more times by Rd; which are generally interacting with MALT1 proteolytic and/or autoproteolytic activity, and in particular which may inhibit said activity. The present invention further describes the synthesis of said new pyrazolo-pyrimidine derivatives, their use as a medicament, especially by interacting with MALT1 proteolytic and/or auto-proteolytic activity.

Published:

— *with international search report (Art. 21(3))*